Post hoc comparisons indicate the HDL LCAT activity was reduced in MCI patients relative to the controls (1.03 ± 0.08 vs. 1.09 ± 0.09, p = 0.012, Figure 2C) and reduced in AD patients vs. the controls (1.03 ± 0.07 vs. 1.09 ± 0.09, p = 0.004), with no difference between MCI and AD patients (p = 0.995). Here, LCAT is linked to Alzheimer disease.